{"id":"https://openalex.org/W2800368387","doi":"https://doi.org/10.1158/1538-7445.am2019-545","title":"Abstract 545: Preclinical development of a bispecific antibody-trap selectively targeting CD47 and CD20 for the treatment of B cell lineage cancer","display_name":"Abstract 545: Preclinical development of a bispecific antibody-trap selectively targeting CD47 and CD20 for the treatment of B cell lineage cancer","publication_year":2019,"publication_date":"2019-07-01","ids":{"openalex":"https://openalex.org/W2800368387","doi":"https://doi.org/10.1158/1538-7445.am2019-545","mag":"2800368387"},"language":"en","primary_location":{"id":"doi:10.1158/1538-7445.am2019-545","doi":"https://doi.org/10.1158/1538-7445.am2019-545","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2019-545","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5026718794","display_name":"Wenzhi Tian","orcid":"https://orcid.org/0000-0002-1986-4381","observed_orcids":["https://orcid.org/0000-0002-1986-4381","https://orcid.org/0009-0002-9733-0956"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Wenzhi Tian","raw_affiliation_strings":["ImmuneOnco Biopharma, Shanghai, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"ImmuneOnco Biopharma, Shanghai, China","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100448223","display_name":"Song Li","orcid":"https://orcid.org/0000-0003-1658-949X","observed_orcids":["https://orcid.org/0000-0003-1658-949X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Song Li","raw_affiliation_strings":["ImmuneOnco Biopharma, Shanghai, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"ImmuneOnco Biopharma, Shanghai, China","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000096572","display_name":"Dianze Chen","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Dianze Chen","raw_affiliation_strings":["ImmuneOnco Biopharma, Shanghai, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"ImmuneOnco Biopharma, Shanghai, China","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110556761","display_name":"Guangjun Liang","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Guangjun Liang","raw_affiliation_strings":["ImmuneOnco Biopharma, Shanghai, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"ImmuneOnco Biopharma, Shanghai, China","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100425554","display_name":"Li Zhang","orcid":"https://orcid.org/0000-0002-3617-2627","observed_orcids":["https://orcid.org/0000-0002-3617-2627","https://orcid.org/0000-0003-2756-2620","https://orcid.org/0009-0001-8129-4308"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Li Zhang","raw_affiliation_strings":["ImmuneOnco Biopharma, Shanghai, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"ImmuneOnco Biopharma, Shanghai, China","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100452051","display_name":"Wei Zhang","orcid":"https://orcid.org/0000-0002-9262-849X","observed_orcids":["https://orcid.org/0000-0002-9262-849X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Wei Zhang","raw_affiliation_strings":["ImmuneOnco Biopharma, Shanghai, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"ImmuneOnco Biopharma, Shanghai, China","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5061835822","display_name":"TU Xiao-ping","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Xiaoping Tu","raw_affiliation_strings":["ImmuneOnco Biopharma, Shanghai, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"ImmuneOnco Biopharma, Shanghai, China","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5016684571","display_name":"Liang Peng","orcid":"https://orcid.org/0000-0003-1682-7064","observed_orcids":["https://orcid.org/0000-0003-1682-7064"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Liang Peng","raw_affiliation_strings":["ImmuneOnco Biopharma, Shanghai, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"ImmuneOnco Biopharma, Shanghai, China","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5060366001","display_name":"Jie Weng","orcid":"https://orcid.org/0000-0002-7034-3215","observed_orcids":["https://orcid.org/0000-0002-7034-3215"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jie Weng","raw_affiliation_strings":["ImmuneOnco Biopharma, Shanghai, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"ImmuneOnco Biopharma, Shanghai, China","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112411214","display_name":"Gui Zhao","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Gui Zhao","raw_affiliation_strings":["ImmuneOnco Biopharma, Shanghai, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"ImmuneOnco Biopharma, Shanghai, China","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100327105","display_name":"Dandan Liu","orcid":"https://orcid.org/0000-0002-2090-9217","observed_orcids":["https://orcid.org/0000-0002-2090-9217"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Dandan Liu","raw_affiliation_strings":["ImmuneOnco Biopharma, Shanghai, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"ImmuneOnco Biopharma, Shanghai, China","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101605101","display_name":"Huiqin Guo","orcid":"https://orcid.org/0000-0002-6498-4497","observed_orcids":["https://orcid.org/0000-0002-6498-4497"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Huiqin Guo","raw_affiliation_strings":["ImmuneOnco Biopharma, Shanghai, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"ImmuneOnco Biopharma, Shanghai, China","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101826262","display_name":"Chunmei Yang","orcid":"https://orcid.org/0000-0003-4810-1049","observed_orcids":["https://orcid.org/0000-0003-4810-1049"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Chunmei Yang","raw_affiliation_strings":["ImmuneOnco Biopharma, Shanghai, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"ImmuneOnco Biopharma, Shanghai, China","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5008944253","display_name":"Ruliang Zhang","orcid":"https://orcid.org/0000-0003-1018-8134","observed_orcids":["https://orcid.org/0000-0003-1018-8134"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ruliang Zhang","raw_affiliation_strings":["ImmuneOnco Biopharma, Shanghai, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"ImmuneOnco Biopharma, Shanghai, China","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":7,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"79","issue":"13_Supplement","first_page":"545","last_page":"545"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12672","display_name":"Phagocytosis and Immune Regulation","score":0.9878000020980835,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T12672","display_name":"Phagocytosis and Immune Regulation","score":0.9878000020980835,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.007499999832361937,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12534","display_name":"Protein Degradation and Inhibitors","score":0.0005000000237487257,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/cd47","display_name":"CD47","score":0.843999981880188},{"id":"https://openalex.org/keywords/cd20","display_name":"CD20","score":0.996999979019165},{"id":"https://openalex.org/keywords/antibody-dependent-cellular-cytotoxicity","display_name":"antibody-dependent cellular cytotoxicity","score":0.6430000066757202},{"id":"https://openalex.org/keywords/phagocytosis","display_name":"phagocytosis","score":0.8240000009536743},{"id":"https://openalex.org/keywords/hemotoxicity","display_name":"hemotoxicity","score":0.7639999985694885},{"id":"https://openalex.org/keywords/rituximab","display_name":"rituximab","score":0.8429999947547913},{"id":"https://openalex.org/keywords/cancer-immunotherapy","display_name":"cancer immunotherapy","score":0.593999981880188},{"id":"https://openalex.org/keywords/tumor-growth-inhibition","display_name":"tumor growth inhibition","score":0.5109999775886536}],"concepts":[{"id":"https://openalex.org/C2780104668","wikidata":"https://www.wikidata.org/wiki/Q21108354","display_name":"CD47","level":3,"score":0.9088636040687561},{"id":"https://openalex.org/C40677261","wikidata":"https://www.wikidata.org/wiki/Q21418091","display_name":"Antibody-dependent cell-mediated cytotoxicity","level":4,"score":0.6031153202056885},{"id":"https://openalex.org/C542903549","wikidata":"https://www.wikidata.org/wiki/Q422248","display_name":"Monoclonal antibody","level":3,"score":0.5600881576538086},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.5553624629974365},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.5398144125938416},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.5162989497184753},{"id":"https://openalex.org/C147483822","wikidata":"https://www.wikidata.org/wiki/Q103537","display_name":"Antigen","level":2,"score":0.5037831664085388},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.5034956336021423},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5013222694396973},{"id":"https://openalex.org/C18031839","wikidata":"https://www.wikidata.org/wiki/Q5009796","display_name":"CD20","level":3,"score":0.488931804895401},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.45360809564590454},{"id":"https://openalex.org/C207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","level":2,"score":0.426657497882843},{"id":"https://openalex.org/C2780674031","wikidata":"https://www.wikidata.org/wiki/Q2012719","display_name":"Cancer immunotherapy","level":4,"score":0.4211730659008026},{"id":"https://openalex.org/C2780653079","wikidata":"https://www.wikidata.org/wiki/Q412323","display_name":"Rituximab","level":3,"score":0.41814157366752625},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.27684515714645386},{"id":"https://openalex.org/C150903083","wikidata":"https://www.wikidata.org/wiki/Q7108","display_name":"Biotechnology","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1538-7445.am2019-545","doi":"https://doi.org/10.1158/1538-7445.am2019-545","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2019-545","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9940000176429749,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4388072076","https://openalex.org/W4312208116","https://openalex.org/W4393987776","https://openalex.org/W4282963473","https://openalex.org/W2802794587","https://openalex.org/W4391786534","https://openalex.org/W4379654696","https://openalex.org/W2993652182","https://openalex.org/W4310119372","https://openalex.org/W3199671843"],"abstract_inverted_index":{"Abstract":[0],"Tumor":[1],"cells":[2,46,89,171],"over":[3,123],"expressing":[4],"CD47":[5,38,84,106,301],"can":[6],"evade":[7],"immune":[8],"surveillance":[9],"through":[10],"delivering":[11],"a":[12,24,59,75,209,296],"\u201cDon\u2019t":[13],"eat":[14],"me\u201d":[15],"signal":[16],"to":[17,33,81,93,104,166],"macrophages.":[18],"Developing":[19],"CD47-targeted":[20,240],"modalities":[21],"has":[22,119,136,197],"been":[23,198],"hot":[25],"pursue":[26],"in":[27,39,43,97,205],"the":[28,34,169,201,259,305,316],"pharmaceutical":[29],"industry.":[30],"However":[31],"due":[32],"ubiquitous":[35],"expression":[36],"of":[37,154,168,175,188,246,295,307,315],"normal":[40],"tissues,":[41],"especially":[42],"red":[44],"blood":[45],"(RBC),":[47],"severe":[48],"antigenic":[49],"sink":[50],"as":[51,53,219,221,250,252],"well":[52,220,251],"hemotoxicity":[54,216],"including":[55],"anemia":[56,253],"set":[57],"up":[58],"higher":[60],"bar":[61],"for":[62,200,239,304,319],"this":[63],"particular":[64],"targeted":[65],"therapy":[66],"development.":[67],"To":[68],"overcome":[69],"these":[70],"hurdles,":[71],"we":[72],"have":[73],"developed":[74],"bispecific":[76,297],"recombinant":[77],"antibody-trap,":[78],"IMM0306,":[79],"designed":[80],"simultaneously":[82],"target":[83,125],"and":[85,107,127,164,185,190,302],"CD20":[86,108,303],"on":[87],"B":[88,308],"but":[90,118],"avoid":[91],"binding":[92,138,148],"human":[94,143],"RBCs.":[95,152],"Extensive":[96],"vitro":[98],"characterization":[99],"demonstrated":[100,208],"that":[101,230],"IMM0306":[102,135,159,233],"binds":[103],"both":[105],"with":[109,158,213,258],"affinity":[110],"3-8":[111],"folds":[112],"lower":[113,147],"than":[114,132,183,186],"either":[115],"single-targeted":[116],"molecule,":[117],"strong":[120],"pro-phagocytosis":[121],"activity":[122,131,139,149],"CD47-positive":[124],"cells,":[126],"even":[128],"stronger":[129],"ADCC":[130],"Rituximab.":[133],"Intriguingly,":[134],"no":[137,214],"at":[140,224],"all":[141],"toward":[142,150],"RBCs,":[144],"albeit":[145],"much":[146,180],"monkey":[151],"Treatment":[153],"tumor-implanted":[155],"SCID":[156],"mice":[157],"significantly":[160],"inhibited":[161],"tumor":[162,170],"growth":[163],"led":[165],"eradication":[167],"from":[172],"5":[173],"out":[174],"8":[176],"mice,":[177],"which":[178],"is":[179],"more":[181],"effective":[182],"Rituximab":[184,189],"co-administration":[187],"SIRP\u03b1-Fc":[191],"(IMM01),":[192],"although":[193],"profound":[194],"synergistic":[195],"effect":[196],"observed":[199],"co-administration.":[202],"Preclinical":[203,293],"study":[204,228],"non-human":[206],"primates":[207],"favorable":[210],"pharmacokinetic":[211],"profile":[212],"obvious":[215],"following":[217],"single":[218],"multiple":[222],"administrations":[223],"different":[225],"dosage.":[226],"Our":[227],"suggests":[229],"antibody-trap":[231,298],"like":[232],"might":[234],"be":[235,255],"an":[236],"ideal":[237],"approach":[238],"immunotherapy":[241],"development":[242,294],"since":[243],"selective":[244],"avoidance":[245],"RBC":[247],"mediated":[248],"antigen-sink":[249],"could":[254],"achieved":[256],"along":[257],"robust":[260],"anti-tumor":[261],"activity.":[262],"Citation":[263],"Format:":[264],"Wenzhi":[265],"Tian,":[266],"Song":[267],"Li,":[268],"Dianze":[269],"Chen,":[270],"Guangjun":[271],"Liang,":[272],"Li":[273],"Zhang,":[274,276],"Wei":[275],"Xiaoping":[277],"Tu,":[278],"Liang":[279],"Peng,":[280],"Jie":[281],"Weng,":[282],"Gui":[283],"Zhao,":[284],"Dandan":[285],"Liu,":[286],"Huiqin":[287],"Guo,":[288],"Chunmei":[289],"Yang,":[290],"Ruliang":[291],"Zhang.":[292],"selectively":[299],"targeting":[300],"treatment":[306],"cell":[309],"lineage":[310],"cancer":[311],"[abstract].":[312],"In:":[313],"Proceedings":[314],"American":[317],"Association":[318],"Cancer":[320,334],"Research":[321],"Annual":[322],"Meeting":[323],"2019;":[324],"2019":[325],"Mar":[326],"29-Apr":[327],"3;":[328],"Atlanta,":[329],"GA.":[330],"Philadelphia":[331],"(PA):":[332],"AACR;":[333],"Res":[335],"2019;79(13":[336],"Suppl):Abstract":[337],"nr":[338],"545.":[339]},"counts_by_year":[{"year":2023,"cited_by_count":2},{"year":2022,"cited_by_count":2},{"year":2021,"cited_by_count":3}],"updated_date":"2026-10-29T09:56:32.521200","created_date":"2018-05-17T00:00:00"}